- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04702971
Decoding Pain Sensitivity in Migraine With Multimodal Brainstem-based Neurosignature
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Migraine causes a tremendous disease burden around the world. Migraine is one of the most prevalent neurological disorders and is reported by the WHO as the second leading cause of disease-related disabilities globally (No. 1 in the population under the 50s). There has been no much change in the ranking of disability for migraine for the past two decades, reflecting an unmet need for better treatment options. Even with the recently available calcitonin-gene related peptide (CGRP)-based treatment, the treatment response versus placebo is still disappointing (6.4-17.6% in acute treatment, 10.2-23.7% in preventive treatment). There is an urgent need to push further the current understanding of the pathophysiology of migraine, based on which novel treatment strategies can be developed. The lack of appropriate research tools hinders the acceleration of migraine research. As a neurological disorder, many neuroimaging studies have been focused on brain alterations; however, the majority focused on the cerebrum. Limited by the currently available neuroimaging and electrophysiological technologies, the deep brain structures especially the brainstem involved in the sensory and nociceptive neurotransmission in migraine, such as the trigeminal nucleus, could only be investigated to a limited extent. Obviously, there is an unmet need for novel technologies that can be used to delineate structural or functional alterations in the brainstem. Elucidation of the role of these deep brain structures may fill the gap in the current understanding of migraine pathophysiology, and pave the way to precise and efficient treatment. Studies restricted to single methodologies are insufficient for the complexity of migraine. Migraine is a complex and dynamic disorder. However, most prior studies were limited to single methodologies and provided limited insights into such a multifaceted disorder. Studies with an integrated approach are lacking. An exhaustive examination of the discrete components of a phenotype, i.e., 'deep phenotyping', can help understand different aspects of its clinical manifestations, and facilitate patient classification. Coupled with neuroimaging and electrophysiological research methodologies, a multi-modal decoding approach would help identify a constellation of migraine-specific biosignatures, rather than just one. This can not only provide clues to decipher migraine pathophysiology in various dimensions but also serve as the basis of the development of a prediction algorithm that can be applied in clinical practice. To pursue the overall goal, the present project schemes as a composition of the following 5 aims:
Aim 1: Deep phenotyping for sensory processing in patients with migraine Aim 2: Brainstem-based functional and structural connectomics in migraine Aim 3: Capturing brainstem electro-neurosignature in migraine Aim 4: Constructing a data fusion platform and developing an EEG cap with a built-in analytic chip Aim 5: Exploring brainstem-based connectome sequencing in migraine animal model
Type d'étude
Inscription (Anticipé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Shuu-Jiun Wang
- Numéro de téléphone: 28712121
- E-mail: k123wang@gmail.com
Sauvegarde des contacts de l'étude
- Nom: Li-Ling Pan
- E-mail: hope881212@hotmail.com
Lieux d'étude
-
-
-
Taipei, Taïwan, 112
- Recrutement
- Headache Center, Teipei Veterans General Hospital
-
Contact:
- Shuu-Jiun Wang, MD
- Numéro de téléphone: 7578 +886-2-28712121
- E-mail: sjwang@vghtpe.gov.tw
-
Contact:
- Li-Ling Pan, Ph.D.
- Numéro de téléphone: 1291 +886-2-28712121
- E-mail: hope881212@hotmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Migraine:
Inclusion criteria:
- fulfill the diagnostic criteria of migraine in ICHD-3,
- 20-65 yrs,
- understand the study design and willing to join the study
- at least four headache days per month,
- the onset of headache is prior to 50 yrs.,
- normal neurological examination findings.
Exclusion criteria:
- history or family history of epilepsy,
- taking migraine prophylactics,
- women who are breastfeeding or pregnant,
- severe psychological disorders, including major depression, PTSD, personality disorders, bipolar disorder, schizophrenia,
- medical, neurological or psychiatric disease discovered by the researcher that would hinder the research,
- contraindications for MR scan (pacemaker, claustrophobia, stent, metal implants…).
Healthy:
Inclusion criteria:
- 20-65 yrs,
- normal neurological examination findings,
- understand the study design and willing to join the study.
Exclusion criteria:
- history or family history of epilepsy,
- women who are breastfeeding or pregnant,
- severe psychological disorders, including major depression, PTSD, personality disorders, bipolar disorder, schizophrenia,
- medical, neurological or psychiatric disease discovered by the researcher that would hinder the research,
- contraindications for MR scan (pacemaker, claustrophobia, stent, metal implants…),
- history of headache will be included (the tension-type headache occurs < 1 time per month is allowed)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: patients with migraine
patient with migraine will be prescribed with flunarizine or routine clinical care per clinician's decision based on the condition of each individual patient
|
The flunarizine will be given per clinical routine
|
|
Autre: healthy control
|
no intervention for healthy control
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Clinical change after treatment (1) headache frequency
Délai: 6 months
|
clinical change (headache frequency) after treatment unit: attacks per month analysis: comparing the mean headache frequency in each month after treatment (M1/M2/M3/M4/M5/M6) to that before treatment (M0)
|
6 months
|
|
Clinical change after treatment (2) headache intensity
Délai: 6 months
|
clinical change (headache intensity) after treatment unit: NRS (numeric rating scale, 0-10) analysis: comparing the mean headache intensity in each month after treatment (M1/M2/M3/M4/M5/M6) to that before treatment (M0)
|
6 months
|
|
Clinical change after treatment (3) headache duration
Délai: 6 months
|
clinical change (headache duration) after treatment unit: hours/day analysis: comparing the mean headache duration (hours/day) in each month after treatment (M1/M2/M3/M4/M5/M6) to that before treatment (M0)
|
6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
EEG change after treatment (1) Linear analysis of EEG before and after treatment
Délai: 12 months
|
power spectral density change of EEG before and after treatment • Four EEG sessions will be arranged. The first one is done before treatment, and the 2nd/3rd/4th one will be done after a 3-month/6-month/12-month treatment course, respectively. |
12 months
|
|
EEG change after treatment (2) Nonlinear analysis of EEG before and after treatment
Délai: 12 months
|
functional connectivity change of EEG before and after treatment • Four EEG sessions will be arranged. The first one is done before treatment, and the 2nd/3rd/4th one will be done after a 3-month/6-month/12-month treatment course, respectively. |
12 months
|
|
EEG change after treatment (3) Nonlinear analysis of EEG before and after treatment
Délai: 12 months
|
evoked potential amplitude change of EEG before and after treatment • Four EEG sessions will be arranged. The first one is done before treatment, and the 2nd/3rd/4th one will be done after a 3-month/6-month/12-month treatment course, respectively. |
12 months
|
|
Sensory threshold change after treatment
Délai: 12 months
|
Using quantitative sensory testing (QST) to evaluate the sensory threshold before and after treatment • Four standard QST sessions will be arranged. The first one is done before treatment, and the 2nd/3rd/4th one will be done after a 3-month/6-month/12-month treatment course, respectively. |
12 months
|
|
fMRI change after treatment (1)
Délai: 12 months
|
functional connectivity change of fMRI before and after treatment • Three fMRI sessions will be arranged. The first one is done before treatment, and the 2nd/3rd one will be done after a 6-month/12-month treatment course, respectively. |
12 months
|
|
fMRI change after treatment (2)
Délai: 12 months
|
activation change of fMRI before and after treatment • Three fMRI sessions will be arranged. The first one is done before treatment, and the 2nd/3rd one will be done after a 6-month/12-month treatment course, respectively. |
12 months
|
|
MRI change after treatment (1)
Délai: 12 months
|
VBM changes of MRI before and after treatment • Three MRI sessions will be arranged. The first one is done before treatment, and the 2nd/3rd one will be done after a 6-month/12-month treatment course, respectively. |
12 months
|
|
MRI change after treatment (2)
Délai: 12 months
|
SBM changes of MRI before and after treatment • Three MRI sessions will be arranged. The first one is done before treatment, and the 2nd/3rd one will be done after a 6-month/12-month treatment course, respectively. |
12 months
|
|
Humoral change after treatment (1)
Délai: 12 months
|
Test the cytokine level using ELISA kit to evaluate the status before and after treatment • Four blood test sessions and saliva collection will be arranged. The first one is done before treatment, and the 2nd/3rd/4th one will be done after a 3-month/6-month/12-month treatment course, respectively. |
12 months
|
|
Humoral change after treatment (2)
Délai: 12 months
|
Test the hormone level using ELISA kit to evaluate the status before and after treatment • Four blood test sessions and saliva collection will be arranged. The first one is done before treatment, and the 2nd/3rd/4th one will be done after a 3-month/6-month/12-month treatment course, respectively. |
12 months
|
|
Genetic variance
Délai: 5 minutes
|
Genetic variants associated with baseline demographics and treatment response as assessed with genome-wide association study using the genotyping data derived from the Axiom Genome-wide array • Blood draw before the treatment to extract DNA for further sequencing |
5 minutes
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Céphalées, primaires
- Troubles de la tête
- Troubles migraineux
- Effets physiologiques des médicaments
- Agents neurotransmetteurs
- Mécanismes moléculaires de l'action pharmacologique
- Agents vasodilatateurs
- Modulateurs de transport membranaire
- Anticonvulsivants
- Hormones et agents régulateurs du calcium
- Bloqueurs de canaux calciques
- Antagonistes de l'histamine H1
- Antagonistes de l'histamine
- Agents d'histamine
- Flunarizine
Autres numéros d'identification d'étude
- 2020-11-004C
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .